Mayo Clinic researchers conducted a study comparing the efficacy of multitarget stool DNA tests to fecal immunochemical testing for colorectal cancer screening in Alaska Native people. Here are six ...

Stool-based DNA testing can help bridge CRC screening gaps between rural and urban populations by providing timely follow-up. The study found no significant difference in follow-up times for ...

Please provide your email address to receive an email when new articles are posted on . The multitarget stool DNA test had a positive predictive value of 31.4% for detecting advanced adenomas.

Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the ...

CT colonography reduced the incidence of colorectal cancer by up to 75% versus no screening, while stool DNA testing reduced the incidence by 59%. Stool testing was cost-effective relative to no ...

October 9, 2008 — Stool DNA testing is a new approach to screening for colorectal cancer, but it is an evolving technology. A study has found that the first-generation stool DNA test (SDT-1) is not ...

Colon CT scans might be able to prevent more colon cancers than stool DNA testing Two CT screening approaches outperformed stool DNA testing in computer models CT screening also was more ...

An investigational multitarget stool DNA test for screening colorectal cancer detects significantly more cancers than the currently available fecal immunochemical test (FIT), researchers report. But ...

Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries ...

Compared to stool DNA testing, researchers found that CT colonography is a cost-saving and clinically effective method for colorectal cancer screening, according to a study was published today in ...

Equity analysis of clinical oncology treatment pathways usage in an integrated health care delivery system. Actionability of genomic alterations in the Molecular Screening and Therapeutics (MoST) ...

(Details of stool collection and processing for DNA testing are shown in Fig. S1 in the Supplementary Appendix, available at NEJM.org.) Buffered stool samples were homogenized, separated into aliquots ...